@article {7095,
	title = {Waldenstr{\"o}m{\textquoteright}s macroglobulinemia: A clinical perspective in the era of novel therapeutics},
	journal = {Annals of Oncology},
	volume = {27},
	year = {2016},
	note = {Cited By :2Export Date: 18 February 2017References: Swerdlow, S.H., Campo, E., Harris, N.L., (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, , Lyon, France: IARC Press;Leblebjian, H., Agarwal, A., Ghobrial, I., Novel treatment options for Waldenstr{\"o}m macroglobulinemia (2013) Clin Lymphoma Myeloma Leuk, 13, pp. S310-S316; 
Treon, S.P., Hunter, Z.R., Aggarwal, A., Characterization of familial Waldenstrom{\textquoteright}s macroglobulinemia (2006) Ann Oncol, 17, pp. 488-494; 
Kristinsson, S.Y., Bjorkholm, M., Goldin, L.R., Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstr{\"o}m macroglobulinemia patients: a population-based study in Sweden (2008) Blood, 112, pp. 3052-3056; 
Treon, S.P., Cao, Y., Yang, G., Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia (2014) Blood, 123, pp. 2791-2796; 
Buske, C., Leblond, V., How to manage Waldenstrom{\textquoteright}s macroglobulinemia (2013) Leukemia, 27, pp. 762-772; 
Dimopoulos, M.A., Kastritis, E., Owen, R.G., Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus (2014) Blood, 124, pp. 1404-1409; 
(2015), http://www.nccn.org/professionals/physician_gls/pdf/waldenstroms.pdf, Waldenstrom{\textquoteright}s macroglobulinemia/ lymphoplasmacytic lymphoma, version 2, 17 October 2014, date last accessedDimopoulos, M.A., Zervas, C., Zomas, A., Extended rituximab therapy for previously untreated patients with Waldenstr{\"o}m{\textquoteright}s macroglobulinemia (2002) Clin Lymphoma, 3, pp. 163-166; 
Treon, S.P., Hanzis, C., Manning, R.J., Maintenance rituximab is associated with improved clinical outcome in rituximab na{\"\i}ve patients with Waldenstrom macroglobulinaemia who respond to a rituximab-containing regimen (2011) Br J Haematol, 154, pp. 357-362; 
Gupta, I.V., Jewell, R.C., Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies (2012) Ann N Y Acad Sci, 1263, pp. 43-56; 
Treon, S.P., Soumerai, J.D., Hunter, Z.R., Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab (2011) Blood, 118, pp. 276-281; 
Treon, S.P., Ioakimidis, L., Soumerai, J.D., Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180 (2009) J Clin Oncol, 27, pp. 3830-3835; 
Dimopoulos, M.A., Garcia-Sanz, R., Gavriatopoulou, M., Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN) (2013) Blood, 122, pp. 3276-3282; 
Ghobrial, I.M., Xie, W., Padmanabhan, S., Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstr{\"o}m Macroglobulinemia (2010) Am J Hematol, 85, pp. 670-674; 
Ghobrial, I.M., Hong, F., Padmanabhan, S., Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia (2010) J Clin Oncol, 28, pp. 1422-1428; 
Treon, S.P., Tripsas, C.K., Meid, K., Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstr{\"o}m{\textquoteright}s macroglobulinemia (2014) Blood, 124, pp. 503-510; 
Treon, S.P., Soumeral, J.D., Branagan, A.R., Thalidomide and rituximab in Waldenstrom macroglobulinemia (2008) Blood, 112, pp. 4452-4457; 
Treon, S.P., Soumerai, J.D., Branagan, A.R., Lenalidomide and rituximab in Waldenstrom{\textquoteright}s macroglobulinemia (2009) Clin Cancer Res, 15, pp. 355-360; 
Treon, S.P., Tripsas, C.K., Meid, K., Prospective, multicenter study of the Mtor inhibitor everolimus (RAD001) as primary therapy in Waldenstrom{\textquoteright}s macroglobulinemia (2013) Blood, 122. , Abstr 1822; 
Ghobrial, I.M., Witzig, T.E., Gertz, M., Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia (2014) Am J Hematol, 89, pp. 237-242; 
Ghobrial, I.M., Moreau, P., Harris, B., A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstr{\"o}m macroglobulinemia (2012) Clin Cancer Res, 18, pp. 5043-5050; 
Ghobrial, I.M., Roccaro, A., Hong, F., Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom{\textquoteright}s macroglobulinemia (2010) Clin Cancer Res, 16, pp. 1033-1041; 
Treon, S.P., Tripsas, C.K., Meid, K., Ibrutinib in previously treated Waldenstr{\"o}m{\textquoteright}s macroglobulinemia (2015) N Engl J Med, 372, pp. 1430-1440; 
Ghobrial, I.M., Campigotto, F., Murphy, T.J., Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/ refractory Waldenstr{\"o}m macroglobulinemia (2013) Blood, 121, pp. 1296-1303; 
(2014) US Prescribing Information, , RITUXAN{\textregistered} (rituximab), Biogen Idec, Inc. and Genentech, Inc. August; 
Dimopoulos, M.A., Agagnostopoulos, A., Kyrtsonis, M.C., Primary treatment of Waldenstr{\"o}m macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide (2007) J Clin Oncol, 25, pp. 3344-3349; 
Dimopoulos, M.A., Roussou, M., Kastritis, E., Primary treatment of Waldenstrom{\textquoteright}s macroglobulinemia with dexamethasone, rituximab and cyclophosphamide (DRC):final analysis of a phase II study (2012) Blood (ASH Annual Meeting Abstracts), 120 (21). , Abstr 438; 
Rummel, M.J., von Gruenhagen, U., Niederle, N., (2008) Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with Waldenstrom{\textquoteright}s macroglobulinemia: first interim results of a randomized phase III study of the Study Group Indolent Lymphomas (StiL) [abstract], , Presented at the 5th International Workshop on Waldenstrom{\textquoteright}s macroglobulinemia; 15-18 October, Stockholm, Sweden. Abstract 139; 
Treon, S.P., Hanzis, C., Tripsas, C., Bendamustine therapy in patients with relapsed or refractory Waldenstrom{\textquoteright}s macroglobulinemia (2011) Clin Lymphoma Myeloma Leuk, 11, pp. 133-135; 
Furman, R.R., Eradat, H., DiRenzo, C.G., A phase II trial of ofatumumab in subjects with Waldenstrom{\textquoteright}s macroglobulinemia (2011) Blood (ASH Annual Meeting Abstracts), 118. , Abstr 3701; 
(2009) US Prescribing Information, , CAMPATH{\textregistered} (alemtuzumab), Genzyme Corporation; 
Treon, S.P., Kelliher, A., Keele, B., Expression of serotherapy target antigens in Waldenstrom{\textquoteright}s macroglobulinemia: therapeutic applications and considerations (2003) Semin Oncol, 30, pp. 248-252; 
Panwalkar, A., Verstovsek, S., Giles, F., Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies (2004) Cancer, 100, pp. 1578-1589; 
(2014) US Prescribing Information, , VELCADE{\textregistered} (bortezomib), Millenium Pharmaceuticals, Inc. October; 
Roccaro, A.M., Leleu, X., Sacco, A., Jia, X., Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia (2008) Blood, 111, pp. 4752-4763; 
(2012) US Prescribing Information, , KYPROLIS{\texttrademark} (carfilzomib), Onyx Pharmaceuticals, Inc. July; 
Siegel, D.S., Kaufman, J.L., Raje, N.S., Updated results from a multicenter, openlabel, dose-escalation phase 1b/2 study of single-agent oprozomib in patients with Waldenstr{\"o}m macroglobulinemia (WM) (2014) Blood, 124, p. 1715; 
Dimopoulos, M.A., Zomas, A., Viniou, N.A., Treatment of Waldenstrom{\textquoteright}s macroglobulinemia with thalidomide (2001) J Clin Oncol, 19, pp. 3596-3601; 
Leleu, X., Legouill, S., Louni, C., Lenalidomide is safe and active in Waldenstrom macroglobulinemia (2014) Blood, 124, p. 4478; 
Leleu, X., Jia, X., Runnels, J., The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia (2007) Blood, 110, pp. 4417-4426; 
Kastritis, E., Terpos, E., Dimopoulos, M.A., Emerging drugs for Waldenstr{\"o}m{\textquoteright}s macroglobulinemia (2011) Expert Opin Emerg Drugs, 16, pp. 45-57; 
Yang, G., Zhou, Y., Liu, X., A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstr{\"o}m macroglobulinemia (2013) Blood, 122, pp. 1222-1232; 
(2015) US Prescribing Information, , IMBRUVICA{\texttrademark} (ibrutinib), Pharmacyclics, Inc. January; 
(2015), http://abbvie.mediaroom.com/2015-07-10-IMBRUVICA-ibrutinib-Now-Approved-to-Treat-Waldenstroms-Macroglobulinemiain-Europe, AbbVie. IMBRUVICA{\textregistered} (ibrutinib) now approved to treat Waldenstrom{\textquoteright}s macroglobulinemia in Europe, 10 July, 10 October 2015, date last accessedRoccaro, A.M., Sacco, A., Jia, X., microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia (2010) Blood, 116, pp. 1506-1514; 
(2015) Study of the glutaminase inhibitor CB-839 in hematological tumors, , https://clinicaltrials.gov/ct2/show/NCT02071888, ClinicalTrials.gov, (10 June, date last accessed; 
Owen, R.G., Kyle, R.A., Stone, M.J., Response assessment in Waldenstr{\"o}mmacroglobulinaemia: update from the VIth International Workshop (2013) Br J Haematol, 160, pp. 171-176; 
Treon, S.P., Yang, G., Hanzis, C., Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrommacroglobulinaemia (2011) Br J Haematol, 154, pp. 223-228
},
	month = {2016},
	pages = {233 - 240},
	abstract = {Waldenstr{\"o}m{\textquoteright}s macroglobulinemia (WM) is a rare, low-grade malignancy with no established standard of care. Rituximab regimens are most commonly used, supported by their efficacy in hematologic malignancies, including WM. A growing number of investigational regimens for WM have been evaluated in phase II clinical trials, including single-agent and combination strategies that include newer-generation monoclonal antibodies (ofatumumab and alemtuzumab), proteasome inhibitors (bortezomib and carfilzomib), immunomodulatory agents (thalidomide and lenalidomide), phosphoinositide 3-kinase/protein kinase B (Akt)/mammalian target of rapamycin pathway inhibitors (everolimus and perifosene), a Bruton{\textquoteright}s tyrosine kinase inhibitor (ibrutinib), and a histone deacetylase inhibitor (panobinostat). Other novel agents are in early-stage development for WM. International treatment guidelines for WM suggest suitable regimens in the newly diagnosed and relapsed/refractory settings, in accordance with patient age, disease presentation, and efficacy and safety profiles of particular drugs. These factors must be considered when choosing appropriate therapy for individual patients with WM, to maximize response and prolong survival, while minimizing the risk of adverse events. This review article provides a clinical perspective of the modern management of patients with WM, in the context of available trial data for novel regimens and recently updated treatment guidelines. {\textcopyright} The Author 2015.},
	keywords = {Efficacy, novel agents, safety, Treatment guidelines, Waldenstr{\"o}m{\textquoteright}s macroglobulinemia},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84961675603\&doi=10.1093\%2fannonc\%2fmdv572\&partnerID=40\&md5=8b2e53e61d481c2b1b742cd8ef405a5f},
	author = {Dimopoulos, M.A. and Kastritis, E. and Ghobrial, I.M.}
}
